Hlib Chabaniuk

Vir Biotechnology unveils early Phase 1 data for VIR-5500 in metastatic prostate cancer at ASCO2026

Vir Biotechnology unveils early Phase 1 data for VIR-5500 in metastatic prostate cancer at ASCO2026
Vir Biotechnology reveals early cancer data

Vir Biotechnology announced it has presented early Phase 1 clinical data for its candidate VIR-5500 targeting metastatic prostate cancer at ASCO2026.

The company also highlighted its strategic global collaboration with Astellas to advance the development of what it positions as a potential best-in-class therapeutic. These developments underscore Vir Biotechnology's growing focus on oncology partnerships and novel drug candidates in early-stage research.

Vir Biotechnology previously shared new data at EASL2026 analyzing body mass index effects in chronic hepatitis delta patients from the Phase 2 SOLSTICE study. The company also reported Week 96 results showing continued HDV suppression in the same SOLSTICE Phase 2 trial. These studies reflect Vir’s established focus on antiviral therapy development.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.